Bausch Health Companies (BHC) Share-based Compensation (2009 - 2026)
Bausch Health Companies (BHC) posted Share-based Compensation of $54.0 million for Q2 2026, up 3.85% sequentially from $52.0 million in Q1 2026, and up 17.39% YoY from $46.0 million in Q2 2025.
Bausch Health Companies (BHC) Share-based Compensation (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Share-based Compensation for 18 years, with the latest figure at $54.0 million in Q2 2026.
- Quarterly Share-based Compensation rose 17.39% year-over-year to $54.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $233.0 million (up 37.06% YoY) and the FY2025 annual result came in at $216.0 million, up 44.0% from the prior year.
- Share-based Compensation advanced to $54.0 million in Q2 2026 per BHC's latest filing, from $52.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $84.0 million in Q4 2025 and troughed at $26.0 million in Q2 2022.
- A 5-year average of $40.6 million and a median of $37.0 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation slipped 21.95% in 2022, then jumped 95.35% in 2025.
- Over 5 years, Share-based Compensation stood at $35.0 million in 2022, then dropped by 17.14% to $29.0 million in 2023, then jumped by 48.28% to $43.0 million in 2024, then soared by 95.35% to $84.0 million in 2025, then tumbled by 35.71% to $54.0 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $54.0 million, $52.0 million, and $84.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Bausch Health Companies | 2.56 Bn | 725.13 Mn | 2.10 Bn | 54.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.00 Mn |
| Jun 30, 2026 | 54.00 Mn |
| Mar 31, 2026 | 34.00 Mn |
| Mar 31, 2026 | 34.00 Mn |
| Dec 31, 2025 | 192.00 Mn |
| Dec 31, 2025 | 192.00 Mn |
| Sep 30, 2025 | -65.00 Mn |
| Sep 30, 2025 | -65.00 Mn |
| Jun 30, 2025 | 46.00 Mn |
| Jun 30, 2025 | 46.00 Mn |
| Mar 31, 2025 | 43.00 Mn |
| Mar 31, 2025 | 43.00 Mn |
| Dec 31, 2024 | 127.00 Mn |
| Dec 31, 2024 | 127.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Mar 31, 2024 | 33.00 Mn |
| Mar 31, 2024 | 33.00 Mn |